



Department of Defense US Army Medical Research and Materiel Command

Fiscal Year 2003 Chronic Myelogenous Leukemia Program

Table of Contents

Introduction

Fiscal Year 2003 Chronic Myelogenous Leukemia funded awards

[Exploration - Hypothesis Development Award](#)

Fiscal Year 2003 Chronic Myelogenous Leukemia Program Participants

[Peer Reviewers](#)

[Integration Panel Reviewers \(IP\)](#)

[Ad Hoc Programmatic Reviewers](#)

[Glossary of Terms](#)

Introduction

The US Army Medical Research and Materiel Command is pleased to present the award list of funded projects for the fiscal year 2003 (FY03) Chronic Myelogenous Leukemia Research Program. Award negotiations were completed by September 30, 2004. The awards listed in this document were selected by a competitive two-tier review process. Funding decisions were based on scientific excellence evaluated in the first tier of review, followed by programmatic relevance judged in the second tier. These projects represent a diverse portfolio of scientific research directed toward the program's overall goal of improving (1) the understanding of the basic science of chronic myelogenous leukemia, (2) the diagnosis of chronic myelogenous leukemia, (3) the treatment of chronic myelogenous leukemia, and (4) the quality of life for individuals and their families living with chronic myelogenous leukemia.

Congressional direction for FY03 specified \$4.25 million for chronic myelogenous leukemia research. Following the receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, award recommendations were made, and contract negotiations were completed. The FY03 programmatic strategy indicated the funding of four proposals received from the fiscal year 2002 Investigator-Initiated Award Mechanism and called for an additional award mechanism, the Exploration-Hypothesis Development Award. This award encourages the initial exploration of innovative, untested, and potentially groundbreaking concepts in chronic myelogenous leukemia. Of the 64 proposals received, 18 proposals were funded.

As the funded scientists embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientific advisors, people living with chronic myelogenous leukemia, and the chronic myelogenous leukemia advocacy community. The expertise, vision, and diversity of perspectives of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons living with chronic myelogenous leukemia. It is with great anticipation and excitement that we await the outcomes of this research.

Exploration - Hypothesis Development Award

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Final Budget
CM030006	Dorshkind	Kenneth	California, University of, Los Angeles	Effects of Hematopoietic Lineage and Precursor Age on CML Disease Progression	\$100,000
CM030010	Skorski	Tomasz	Temple University	Does BCR/ABL Induce Self-Mutagenesis to Escape Imatinib Mesylate?	\$100,000
CM030012	Wang	Jean	California, University of, San Diego	Pathogenic Mechanism of Malignant Progression in Chronic Myelogenous Leukemia	\$100,000
CM030014	Chen	Xiuxu	Wisconsin, University of, Madison	Human CD1d-Restricted Natural Killer T (NKT) Cell Cytotoxicity Against Myeloid Cells	\$99,999
CM030018	Muller-Sieburg	Christa	Sidney Kimmel Cancer Center	Myeloid-Biased Stem Cells as Potential Targets for Chronic Myelogenous Leukemia	\$99,999
CM030021	Griffin	Kevin	California, University of, Los Angeles	Creation of a Zebrafish Model of Chronic Myelogenous Leukemia	\$100,000
CM030024	Deininger	Michael	Oregon Health & Science University	Elucidating the Mechanism of p27 Inactivation by the Bcr-Abl Tyrosine Kinase	\$100,000
CM030040	Calabretta	Bruno	Thomas Jefferson University	Differentiation of Myeloid CML-Blast Crisis by C/EBPAlpha	\$75,000
CM030051	Davis	Brian	Ordway Research Institute, Inc.	Functional Assays to Identify Genes that Control CML Growth and Apoptosis by Lentiviral Vector Delivery of Random siRNA Libraries	\$100,000
CM030054	Tremblay	Michel	McGill University	Contribution of Protein Tyrosine Phosphatases to the Ontogeny and Progression of Chronic Myeloid Leukemia	\$97,869
CM030061	Loeb	David	Johns Hopkins University, East Baltimore Campus	Engagement of the Aryl Hydrocarbon Receptor to Modulate WT1 Splicing in CML Cells	\$99,708
CM030062	Wendel	Hans-Guido	Cold Spring Harbor Laboratory	In vivo RNAi Library Screen to Identify Mediators of Disease Progression and Drug Resistance in CML	\$100,000
CM030080	Kornbluth	Sally	Duke University	Inducing Apoptosis in Bcr/Abl-Expressing Cells	\$100,000
CM030085	Tan	Derek	Memorial Sloan-Kettering Cancer Center	Synthesis and Screening of Novel Biased Combinatorial Libraries to Identify Selective Kinase Inhibitors for Dissecting Src and Bcr-Abl Signaling in CML	\$100,000
CM030088	Feldman	Ricardo	Maryland, University of, Baltimore	A Novel Mouse Model for Analysis of CML	\$100,000
CM030094	Oppenheim	Ariella	Hebrew, University of, Jerusalem	siRNA Gene Therapy Approach for Chronic Myelogenous Leukemia Based on SV40 Vectors	\$49,560
CM030097	Baker	David	Washington University	Computationally Designed Protein Therapeutics for the Treatment of STI-571-Resistant Chronic Myelogenous Leukemia	\$100,000

**Fiscal Year 2003 Chronic Myelogenous Leukemia Research Program
Peer Reviewers**

Reviewer	Degree	Institution/Affiliation
Barry, Michael	Ph.D.	Baylor College of Medicine
Bhatia, Ravi	M.D.	City of Hope National Medical Center
Bouhassira, Eric	Ph.D.	Albert Einstein College of Medicine
Carroll, Martin	M.D.	University of Pennsylvania
Clarkson, Bayard	M.D.	Memorial Sloan Kettering Cancer Center
Cranmer, David		The Leukemia & Lymphoma Society
Dickenson, Kelvin		The Leukemia & Lymphoma Society
Jacobson, Matt	Ph.D.	University of California, San Francisco
Jhanwar, Suresh	Ph.D.	Memorial Sloan Kettering Cancer Center
Katsanis, Emmanuel	M.D.	University of Arizona
Kurzrock, Razelle	M.D.	University of Texas, MD Anderson Cancer Center
Lyons, Susan	M.D., Ph.D.	University of Michigan
Melnick, Ari	M.D.	Albert Einstein College of Medicine
Nichols, Gwen	M.D.	Columbia University
Nucifora, Giuseppina	D.Sc., Ph.D.	University of Illinois, Chicago
Orem, Judy		The Leukemia & Lymphoma Society, Oregon
Perrotti, Danilo	M.D., Ph.D.	Ohio State University
Platanias, Leonidas	M.D., Ph.D.	Northwestern University
Smithgall, Thomas	Ph.D.	University of Pittsburgh
Spring, Susan	Ph.D.	Scientific Review Administrator

St. Clair, Daret	Ph.D.	University of Kentucky
Whitehead, Ian	Ph.D.	International Center for Public Health
Wieder, Eric	Ph.D.	University of Texas, MD Anderson Cancer Center

**FISCAL YEAR 2003 CHRONIC MYELOGENOUS LEUKEMIA RESEARCH
PROGRAM INTEGRATION PANEL MEMBERS**

Reviewers	Degree	Institution/Affiliaton
Talpaz, Moshe (Chair)	M.D.	University of Texas M.D. Anderson Cancer Center
Kinniburgh, Alan J. (Acting Chair)	Ph.D.	Leukemia & Lymphoma Society
McCullough, Rose	Ph.D.	U.S. Agency for International Development
Rowley, Janet	M.D.	University of Chicago
Van Etten, Richard A.	M.D., Ph.D.	Tufts-New England Medical Center

**FISCAL YEAR 2003 CHRONIC MYELOGENOUS LEUKEMIA
RESEARCH PROGRAM AD HOC REVIEWERS**

Reviewers	Degree	Institution/Affiliation
Moore, Helen	Ph.D.	American Institute of Mathematics
Radich, Jerald P.	M.D.	Fred Hutchinson Cancer Research Center
Ren, Ruibao	M.D., Ph.D.	Brandeis University

Glossary of Terms

Exploration – Hypothesis Development Award (EHDA): The intent of this award is to provide funds to support the initial exploration of innovative, untested, and potentially groundbreaking concepts in chronic myelogenous leukemia. Results of studies conducted through an EHDA may provide the scientific rationale upon which a new hypothesis can be based or may provide, for example, initial proof of principle of an innovative hypothesis. The award is designed to provide investigators with the opportunity to pursue serendipitous observations. This award is not intended to support ongoing work; therefore, the existence of preliminary data suggests that the research would be more appropriately submitted to a different award mechanism. Successfully completed EHDAs are expected to lead to high-risk, potentially high-gain future research endeavors for this and other funding agencies. Projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b)(4)¹ or eligible for expedited review (45 CFR 46.110, 21 CFR 56.110)². This award is open to investigators at all levels

¹ Title 32, Code of Federal Regulations (CFR), Part 219, Section 101(b)(4). Research involving collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, is considered to be exempt under 32 CFR 219.101(b)(4).

² For additional information, refer to U.S. Department of Health and Human Services' Office of Human Research Protection website at <http://www.hhs.gov/ohrp>.